These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 18301342

  • 1. Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor.
    Durrbach A, Rostaing L, Tricot L, Ouali N, Wolf P, Pouteil-Noble C, Kessler M, Viron B, Thervet E.
    Transplantation; 2008 Feb 15; 85(3):486-90. PubMed ID: 18301342
    [Abstract] [Full Text] [Related]

  • 2. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 3. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
    Oberbauer R, Kreis H, Johnson RW, Mota A, Claesson K, Ruiz JC, Wilczek H, Jamieson N, Henriques AC, Paczek L, Chapman J, Burke JT, Rapamune Maintenance Regimen Study Group.
    Transplantation; 2003 Jul 27; 76(2):364-70. PubMed ID: 12883194
    [Abstract] [Full Text] [Related]

  • 4. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
    Baboolal K.
    Transplantation; 2003 Apr 27; 75(8):1404-8. PubMed ID: 12717239
    [Abstract] [Full Text] [Related]

  • 5. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients.
    Morales JM, Campistol JM, Kreis H, Mourad G, Eris J, Schena FP, Grinyo JM, Nanni G, Andres A, Castaing N, Brault Y, Burke JT.
    Transplant Proc; 2005 Mar 27; 37(2):693-6. PubMed ID: 15848504
    [Abstract] [Full Text] [Related]

  • 6. Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine.
    Morales JM, Hartmann A, Walker R, Arns W, Senatorski G, Grinyó JM, Shoker A, Wilczek H, Jamieson NV, Lelong M, Brault Y, Burke JT, Scarola JA, Rapamune Maintenance Regimen Study Group.
    Transplant Proc; 2009 Mar 27; 41(6):2339-44. PubMed ID: 19715914
    [Abstract] [Full Text] [Related]

  • 7. The combination of sirolimus and cyclosporine does not delay initial renal graft function recovery.
    Hsu HJ, Tian YC, Chen YC, Lai BC, Fang JT, Yang CW, Wu MS.
    Ren Fail; 2008 Mar 27; 30(3):303-6. PubMed ID: 18350450
    [Abstract] [Full Text] [Related]

  • 8. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 9. Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine.
    Romagnoli J, Citterio F, Nanni G, Favi E, Tondolo V, Spagnoletti G, Salerno MP, Castagneto M.
    Transplant Proc; 2006 May 27; 38(4):1034-6. PubMed ID: 16757255
    [Abstract] [Full Text] [Related]

  • 10. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.
    Pliszczynski J, Kahan BD.
    Transplant Proc; 2011 Dec 27; 43(10):3657-68. PubMed ID: 22172822
    [Abstract] [Full Text] [Related]

  • 11. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.
    Oberbauer R, Segoloni G, Campistol JM, Kreis H, Mota A, Lawen J, Russ G, Grinyó JM, Stallone G, Hartmann A, Pinto JR, Chapman J, Burke JT, Brault Y, Neylan JF, Rapamune Maintenance Regimen Study Group.
    Transpl Int; 2005 Jan 27; 18(1):22-8. PubMed ID: 15612979
    [Abstract] [Full Text] [Related]

  • 12. Sirolimus delays recovery from posttransplant renal failure in kidney graft recipients.
    Boratyńska M, Banasik M, Patrzalek D, Szyber P, Klinger M.
    Transplant Proc; 2005 Mar 27; 37(2):839-42. PubMed ID: 15848550
    [Abstract] [Full Text] [Related]

  • 13. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation.
    Stephany BR, Augustine JJ, Krishnamurthi V, Goldfarb DA, Flechner SM, Braun WE, Hricik DE, Dennis VW, Poggio ED.
    Transplantation; 2006 Aug 15; 82(3):368-74. PubMed ID: 16906035
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the safety and efficacy of cyclosporine minimization versus cyclosporine elimination in de novo renal allograft patients receiving sirolimus.
    Tedesco-Silva H, Garcia VD, Contieri FL, De Boni Monteiro de Carvalho D, Noronha IL, Gonçalves RT, de Paula FJ, Abbud-Filho M, Manfro RC, David-Neto E, Alfieri F, Ikehara E, Jiang Q, Tai SS, Medina-Pestana JO.
    Transplant Proc; 2010 Jun 15; 42(5):1659-66. PubMed ID: 20620495
    [Abstract] [Full Text] [Related]

  • 15. Prospective observational study of sirolimus as primary immunosuppression after renal transplantation.
    Pescovitz MD, Nezakatgoo N, Lorber MI, Nashan B, Tedesco-Silva H, Kasiske BL, de la Cruz FJ, Russ G, Campistol J, Keown PA, International Sirolimus Study Group.
    Transplantation; 2009 Oct 27; 88(8):1010-8. PubMed ID: 19855247
    [Abstract] [Full Text] [Related]

  • 16. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
    Ross H, Pflugfelder P, Haddad H, Cantarovich M, White M, Ignaszewski A, Howlett J, Vaillancourt M, Dorent R, Burton JR, CADENCE Study Group.
    J Heart Lung Transplant; 2008 Feb 27; 27(2):197-202. PubMed ID: 18267227
    [Abstract] [Full Text] [Related]

  • 17. Addition of sirolimus to cyclosporine in long-term kidney transplant recipients to withdraw steroid.
    Citterio F, Sparacino V, Altieri P, Rigotti P, Calabrese S, Poli M, Vinti V, Segoloni GP.
    Transplant Proc; 2005 Mar 27; 37(2):827-9. PubMed ID: 15848545
    [Abstract] [Full Text] [Related]

  • 18. Three-year health-related quality-of-life outcomes for sirolimus-treated kidney transplant patients after elimination of cyclosporine.
    Russ G, Jamieson N, Oberbauer R, Arias M, Murgia MG, Blancho G, Sato R, Stoeckl M, Revicki DA.
    Transpl Int; 2007 Oct 27; 20(10):875-83. PubMed ID: 17854445
    [Abstract] [Full Text] [Related]

  • 19. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients.
    Stallone G, Di Paolo S, Schena A, Infante B, Grandaliano G, Battaglia M, Gesualdo L, Schena FP.
    Transplantation; 2003 Apr 15; 75(7):998-1003. PubMed ID: 12698087
    [Abstract] [Full Text] [Related]

  • 20. Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients.
    Felipe CR, Park SI, Pinheiro-Machado PG, Garcia R, Casarini DE, Moreira S, Tedesco-Silva H, Medina-Pestana JO.
    Fundam Clin Pharmacol; 2009 Oct 15; 23(5):625-31. PubMed ID: 19656203
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.